VTU Technology bringing Pichia advances to BPI Europe

Grambach, Austria: – Protein expression specialist VTU Technology is headed for the influential BioProcess International European Summit, BPI Europe, in Amsterdam to share latest advances in its Pichia pastoris recombinant expression technology.

These include new technology developments to VTU’s growing protein production toolbox that offer rich potential for production of biopharmaceuticals.

Safe, clinically validated, well-characterized and CMC-ready Pichia pastoris protein production strains and processes for biopharmaceutical manufacturing.

VTU will demonstrate how biopharma companies benefit from VTU´s CMC compliant technology platform for the safe and effective production of therapeutic candidates.

Pichia pastoris has been approved by major regulatory authorities for the production of biopharmaceuticals and, on top of that, several appealing features render the VTU Pichia platform well suited for the production of biologics.

All components of VTU´s Pichia toolbox, which has already been used to produce proteins for clinical studies, are thoroughly characterized and full documentation is readily available to support regulatory filings for biologic candidates.

Furthermore, Pichia based protein production is no longer limited to non-glycosylated proteins. VTU offers boosted glycoprotein production by combining VTU´s Pichia technology with Pichia Glycoswitch®. Pichia Glycoswitch® enables the production of homogeneous and uniform glycoproteins with Man5- or other human-like glycoforms. The Picha GlycoSwitch® system is based on yeast strains that have been engineered to perform specific glycosylation steps at high fidelity.

Unlocking new production solutions

VTU will be represented at BPI Europe by its Head of Downstream and Analytics and Principal Scientist and Principal Scientist, Dr. Iskandar Dib, who is expert in up- and downstream process development applying DoE tools for process understanding.

Iskandar is accepting requests through the partnering system or by email (see below) from anyone looking to discuss advanced recombinant protein production solutions in Amsterdam.

“I’ll be happy to discuss how we provide unique solutions through an increase in genetic diversity. VTU Technology’s platform stands out due to its potential for expression optimization and debottlenecking with respect to many aspects of protein expression all the way from transcription and translation to translocation, protein folding and secretion thus maximizing yields without compromising product quality,” Iskandar Dib added.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma and life science as well as in the energy industries.

More information: www.vtu-technology.com and www.vtu.com.

About BPI Europe 2018

The BioProcess International European Summit (BPI Europe) is one of the world’s largest events dedicated to bioprocessing, highlighting the sciences, technologies and partners needed to accelerate promising biologics to market.

BPI Europe 2018 is a three-day event opening April 23 at the RAI Conference Center in Amsterdam.

The conference is expected to attract more than 900 scientists and executives representing some 275 companies and organizations working across the entire bioprocessing spectrum. The co-located exhibition will feature more than 160 leading companies.

The event is organized by Knect365 with more information at: https://lifesciences.knect365.com/bpieurope/.